Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations

DR Mould, Thierry Lavé, JP Gibbs, Boy Frame

CPT Pharmacometrics & Systems Pharmacology · 2015 · 76 citations · 69 references

DOIFull text

Open access

Concepts

Abstract

Anticancer agents often have a narrow therapeutic index (TI), requiring precise dosing to ensure sufficient exposure for clinical activity while minimizing toxicity. These agents frequently have complex pharmacology, and combination therapy may cause schedule-specific effects and interactions. We review anticancer drug development, showing how integration of modeling and simulation throughout development can inform anticancer dose selection, potentially improving the late-phase success rate. This article has a companion article in Clinical Pharmacology & Therapeutics with practical examples.

References

69